EC Number |
Expression |
Reference |
---|
3.5.3.18 | more |
DDAH isoforms are expressed in a dynamic,overlapping pattern during embryonic development |
712183 |
3.5.3.18 | up |
alpha-lipoic acid increases the gene expression and activity of DDAH, and signal transducer and activator of transcription STAT3 phosphorylation. Transfection of STAT3 increases DDAH II promoter activity, and alpha-lipoic acid amplifies it. alpha-Lipoic acid-induced increase in DDAH II promoter activity is attenuated in the promoter that has a mutation in the putative STAT3-binding site |
711109 |
3.5.3.18 | up |
DDAH-2 protein expression is higher in osteoarthritic cartilage than in normal cartilage |
718718 |
3.5.3.18 | up |
during growth on asymmetric dimethyl-L-arginine, induction of the DdaH gene is achieved via the putative enhancer-binding protein PA1196 and the alternative sigma factor RpoN. Both PA1196 and RpoN are essential for the expression of the DdaH gene in response to methylarginines |
754016 |
3.5.3.18 | up |
following myocardial infarction, left ventricular DDAH activity is increased to 210% of control |
710771 |
3.5.3.18 | up |
in chondrocyte mitochondria extracts, DDAH-2 expression is significantly increased after exposure to IL-1beta |
718718 |
3.5.3.18 | up |
resveratrol activates silent information regulator SIRT1 and inhibits upregulates the expression of DDAH2 |
752652 |
3.5.3.18 | up |
treatment of mice with farnesoid X receptor agonist 3-(2,6-dichlorophenyl)-4-(3'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole, i.e. GW4064, leads to increased expression of DDAH-1 and cationic amino acid transporter CAT-1 in both liver and kidney |
712845 |